arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Revolution Medicines, Inc.

RVMD

$205.24 ▲ +7.43 (+3.76%) at close

9 Visible periods

28 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Revolution Medicines, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $39.0B

Dividend Yield —

Revenue Growth None

Op. Margin None

ROIC -72.5% ↘

FCF / Share $-4.81 ↘

Trailing P/E —

Price / Book 24.8x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

9-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$0.00

— —

Net Income Profit after all expenses

$-1.13B

↓ -88.5% —

Operating Margin Operating profit as % of sales

-257.5%

↓ -138.1% —

FCF / Share Free cash flow per share

$-4.81

↓ -42.0% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality →

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Revenue Growth YoY (%)	—	N/M	-67.3% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-941%)	20.4% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+155%)	-31.6% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-495%)	-14.1% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-276%)	148.2% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1752%)	—	—
EPS Growth YoY (%)	-66.2% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	7.3% Fair ↑ Fair Improving Year-over-year change in earnings per share Optimal: > 10%	-25.3% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	-19.8% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—
Net Income Growth YoY (%)	-88.5% Weak ↓ Weak Declining Year-over-year change in net income	-37.5% Weak ↑ Weak Improving Year-over-year change in net income	-75.5% Weak → Weak Stable Year-over-year change in net income	-32.9% Weak ↑ Weak Improving Year-over-year change in net income	-73.0% Weak → Weak Stable Year-over-year change in net income	-126.9% Weak Weak Year-over-year change in net income	-14.1% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	-42.0% Weak ↓ Weak Declining Year-over-year change in free cash flow	-6.9% Weak ↑ Weak Improving Year-over-year change in free cash flow	-8.5% Weak Weak Year-over-year change in free cash flow	-38.2% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—
Revenue CAGR 3Y (%)	—	—	-35.4% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	-10.9% Weak Weak Compound annual revenue growth over 3 years	13.4% Good Good Compound annual revenue growth over 3 years	—	—	—	—
Revenue CAGR 5Y (%)	—	—	-10.5% Weak Weak Compound annual revenue growth over 5 years	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Operating Margin (%) (%)	—	—	—	—	—	-257.5% Weak ↓ Weak Declining Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1817%)	-108.2% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-821%)	-200.0% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1433%)	—
Effective Tax Rate (%) (%)	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.1% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.8% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.2% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.3% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	8.4% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—
Profit Margin (%) (%)	—	—	—	—	—	-251.6% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2197%)	-95.2% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-894%)	-207.2% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1827%)	—
FCF Margin (%) (%)	—	—	—	—	—	-239.6% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	-104.3% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-1.4% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—
FCF / Net Income (x)	0.81x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.95x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.82x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.95x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.82x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.95x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	1.10x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	0.01x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Return on Invested Capital (%)	-72.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-30.4% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-26.5% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-37.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-31.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-23.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	32.5% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	29.4% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-50.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-27.0% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-23.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-31.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-25.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-19.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	-24.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-69.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-562%)	-26.5% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-277%)	-23.9% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-259%)	-36.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-342%)	-31.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-307%)	-22.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-252%)	31.2% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+108%)	38.5% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+157%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Interest Coverage (x)	—	—	—	—	-15667.33x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-1559.11x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-510.57x Weak Weak Operating income divided by interest expense Optimal: > 5x	-347.66x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-383.75M	$-543.06M	$-696.15M	$-161.41M	$-108.50M	$-104.27M	$-16.66M	$-69.59M	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Revenue per Share (USD)	$0.00	$0.00	$0.10	$0.44	$0.40	—	—	—	—
Basic EPS, GAAP (USD)	$-5.95	$-3.58	$-3.86	$-3.08	$-2.57	—	—	—	—
Free Cash Flow per Share (USD)	$-4.81	$-3.38	$-3.17	$-2.92	$-2.11	—	—	—	—
Book Value per Share (USD)	$8.28	$12.19	$11.09	$7.58	$8.13	$7.13	$-46.35	—	—
Tangible Book Value per Share (USD)	$7.92	$11.80	$10.65	$6.77	$7.12	$5.99	$-69.62	—	—
Basic Weighted Avg Shares (shares)	190.13M	167.74M	113.15M	80.63M	72.81M	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Working Capital (USD)	$1.78B	$2.16B	$1.74B	$598.20M	$529.42M	$406.95M	$90.93M	—	—
Total Equity (USD)	$1.63B	$2.27B	$1.83B	$685.19M	$602.57M	$474.68M	$-152.57M	$-108.42M	$-67.72M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Sales/Revenue/Turnover (USD)	$0.00	$0.00	$11.58M	$35.38M	$29.39M	$42.98M	$50.04M	$20.16M	—
Depreciation Expense (USD)	$7.40M	$6.20M	$5.04M	$3.97M	$3.08M	$2.61M	$2.27M	$1.57M	—
Net Income, GAAP (USD)	$-1.13B	$-600.09M	$-436.37M	$-248.71M	$-187.09M	$-108.16M	$-47.66M	$-41.79M	—
Operating Cash Flow (USD)	$-897.74M	$-557.44M	$-350.57M	$-224.40M	$-147.18M	$-100.06M	$-49.62M	$1.21M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 9 years · 31 quarters

Revolution Medicines, Inc.

Analytical Summary

9-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare RVMD with peers